Magnetic Resonance Cholangiopancreatography Severity Predicts Disease Outcomes in Pediatric Primary Sclerosing

Kedar Patil1,2, Amanda Ricciuto3,4, Alaa Alsharief1

  • 1Department of Diagnostic Imaging The Hospital for Sick Children Toronto Canada.

Hepatology Communications
|February 7, 2020
PubMed

Insights

Magnetic resonance cholangiopancreatography (MRCP) scores are reliable for assessing pediatric primary sclerosing cholangitis (PSC). An MRCP score combining intrahepatic and extrahepatic duct information predicts complications and liver transplant needs in children with PSC.

Area of Science:

  • Pediatric Gastroenterology and Hepatology
  • Medical Imaging and Diagnostics
  • Biomarker Development

Background:

  • Magnetic resonance cholangiopancreatography (MRCP) has not been validated as a surrogate biomarker in pediatric primary sclerosing cholangitis (PSC).
  • Assessing disease severity and predicting outcomes in pediatric PSC is crucial for timely intervention.

Purpose of the Study:

  • To evaluate the inter-rater reliability, prognostic utility, and construct validity of a modified Majoie classification applied to MRCP in pediatric PSC.
  • To determine if MRCP scores can predict disease complications and the need for liver transplantation.

Main Methods:

  • Retrospective cohort study of 45 children with PSC undergoing MRCP.
  • Six variations of the Majoie classification were applied to MRCP images.
  • Inter-rater reliability assessed using weighted kappas and ICCs; prognostic utility evaluated using survival analysis and c-statistics; construct validity assessed via Spearman correlations.

Main Results:

  • MRCP scores demonstrated substantial to excellent inter-rater reliability (kappas/ICCs, 0.78-0.82).
  • The sum intrahepatic and extrahepatic duct (IHD-EHD) score showed the best predictive ability for PSC complications (c-statistic, 0.80) and liver transplant (LT) (c-statistic, 0.97).
  • Higher MRCP scores were independently associated with increased PSC complications and correlated significantly with fibrosis stage and bilirubin levels.

Conclusions:

  • An MRCP-based score, incorporating the most affected intrahepatic and extrahepatic duct regions, is reliable and prognostic in pediatric PSC.
  • This MRCP scoring system can predict meaningful clinical outcomes, including disease progression and liver transplant necessity.
  • Further prospective validation and responsiveness assessment are recommended for this novel biomarker.